STAT+: Rafael Pharma drug fails to prolong survival of patients with pancreatic cancer in large study
Rafael Pharmaceuticals said Thursday that its experimental treatment for pancreatic cancer failed to prolong the lives of patients in a large clinical trial.
A separate study of the same Rafael drug, called devimistat, involving patients with a type of leukemia, was also stopped early after an interim analysis concluded the drug was not working, the company said.
Continue to STAT+ to read the full story…
